StockData
Jazz Pharmaceuticals plc logo

Jazz Pharmaceuticals plc (JAZZ) stock

JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30122% above fair value
$247.77+7.06 (+2.93%)

Close on Nov 18, 2026Market cap $16.08BP/E 80.7Yield –

Earnings

Jazz Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 23, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$1.24B
+10.4% on a year earlier
Non-GAAP adjusted earnings (loss) per share, Q3 FY2026
-$3.88
$8.13 a year earlier
Latest guidance
Raised
Nov 2, 2026 · 11 items

Quarterly results

Revenue and earnings per share from each of Jazz Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 23, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 2, 2026after the close$1.24B+10.4%-$7.48-$3.88Release
Q2 FY2026ended Jun 30, 2026Aug 3, 2026after the close––––Release
Q1 FY2026ended Mar 31, 2026May 5, 2026after the close$1.07B+19.0%$4.43$6.34Release
Q4 FY2025ended Dec 31, 2025Feb 24, 2026after the close$1.20B+10.1%$3.21$6.64Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025after the close$1.13B+6.7%$4.08$8.13Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025after the close$1.05B+2.6%-$11.74-$8.25Release
Q1 FY2025ended Mar 31, 2025May 6, 2025after the close$898.00M-0.4%-$1.52$1.68Release
Q4 FY2024ended Dec 31, 2024Feb 25, 2025after the close$1.09B+7.5%$3.11$6.60Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024after the close$1.05B+8.5%$3.42$6.61Release
Q2 FY2024ended Jun 30, 2024Jul 31, 2024after the close$1.02B+7.0%$2.49$5.30Release
Q1 FY2024ended Mar 31, 2024May 1, 2024after the close$901.98M+1.0%-$0.23$2.68Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Jazz Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total RevenuesFY2026$4.78B – $4.85B$4.25B – $4.50BRaisedNov 2, 2026
Total RevenuesFY2026$4.25B – $4.50B–NewMay 5, 2026
Gross margin %non-GAAPFY202690.5% – 91.5%90% – 91%RaisedNov 2, 2026
Gross margin %GAAPFY202689% – 90%89% – 90%ReaffirmedNov 2, 2026
Gross margin %GAAPFY202689% – 90%–NewMay 5, 2026
Gross margin %non-GAAPFY202690% – 91%–NewMay 5, 2026
Effective tax rateGAAPFY202620% – 30%0% – 10%RaisedNov 2, 2026
Effective tax ratenon-GAAPFY202619.5% – 21.5%11.5% – 13.5%RaisedNov 2, 2026
Effective tax ratenon-GAAPFY202611.5% – 13.5%–NewMay 5, 2026
Effective tax rateGAAPFY20260% – 10%–NewMay 5, 2026
R&D expensesGAAPFY2026$819.00M – $876.00M$811.00M – $867.00MLoweredNov 2, 2026
R&D expensesnon-GAAPFY2026$725.00M – $775.00M$725.00M – $775.00MLoweredNov 2, 2026
R&D expensesGAAPFY2026$811.00M – $867.00M–LoweredMay 5, 2026
R&D expensesnon-GAAPFY2026$725.00M – $775.00M–LoweredMay 5, 2026
SG&A expensesnon-GAAPFY2026$1.33B – $1.37B$1.26B – $1.32BRaisedNov 2, 2026
SG&A expensesGAAPFY2026$1.54B – $1.60B$1.42B – $1.50BRaisedNov 2, 2026
SG&A expensesGAAPFY2026$1.42B – $1.50B–NewMay 5, 2026
SG&A expensesnon-GAAPFY2026$1.26B – $1.32B–NewMay 5, 2026
Weighted-average diluted shares outstandingnon-GAAPFY202669 – 70–RaisedNov 2, 2026
Weighted-average diluted shares outstandingGAAPFY202669 – 70–RaisedNov 2, 2026
Weighted-average ordinary shares outstandingGAAPFY202666 – 67–NewMay 5, 2026
Weighted-average ordinary shares outstandingnon-GAAPFY202666 – 67–NewMay 5, 2026
Weighted-average ordinary shares outstandingGAAPFY202665 – 66–NewFeb 24, 2026
Weighted-average ordinary shares outstandingnon-GAAPFY202665 – 66–NewFeb 24, 2026

Guidance vs results

The last range Jazz Pharmaceuticals gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025EPS (GAAP)-$7.10 – -$5.20-$5.97Σ4QWithin range
FY2025Net income per diluted share$7.65 – $8.45$8.20Σ4QWithin range
FY2025Revenue$4.18B – $4.28B$4.27BΣ4QWithin range

Guidance history

Every forecast Jazz Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 2, 2026Gross margin %FY202690.5% – 91.5%Raised
Nov 2, 2026Gross margin %FY202689% – 90%Reaffirmed
Nov 2, 2026Weighted-average diluted shares outstandingFY202669 – 70Raised
Nov 2, 2026Effective tax rateFY202620% – 30%Raised
Nov 2, 2026Effective tax rateFY202619.5% – 21.5%Raised
Nov 2, 2026R&D expensesFY2026$819.00M – $876.00MLowered
Nov 2, 2026SG&A expensesFY2026$1.33B – $1.37BRaised
Nov 2, 2026R&D expensesFY2026$725.00M – $775.00MLowered
Nov 2, 2026SG&A expensesFY2026$1.54B – $1.60BRaised
Nov 2, 2026Weighted-average diluted shares outstandingFY202669 – 70Raised
Nov 2, 2026Total RevenuesFY2026$4.78B – $4.85BRaised
May 5, 2026Gross margin %FY202689% – 90%New
May 5, 2026Gross margin %FY202690% – 91%New
May 5, 2026Effective tax rateFY202611.5% – 13.5%New
May 5, 2026Weighted-average ordinary shares outstandingFY202666 – 67New
May 5, 2026Weighted-average ordinary shares outstandingFY202666 – 67New
May 5, 2026Effective tax rateFY20260% – 10%New
May 5, 2026SG&A expensesFY2026$1.42B – $1.50BNew
May 5, 2026R&D expensesFY2026$811.00M – $867.00MLowered
May 5, 2026SG&A expensesFY2026$1.26B – $1.32BNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Jazz Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. News
  4. News
  5. News
  6. Update
  7. Results
  8. Results
  9. Results
  10. Results
  11. News
  12. Results
  13. Results
  14. Update
  15. Results

See a number that looks wrong?